This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
These 3 CEOs Just Bought the Dip
by Derek Lewis
Recently, CEOs of several companies have made splashes, acquiring shares at a discount. What do they know?
Ventas Q2 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises
by Zacks Equity Research
VTR's Q2 results reflect a year-over-year rise in revenues. The total property same-store NOI improves on strong performance across the business segments.
Equinix's Q2 AFFO Beat, Recurring Revenues Rise Y/Y, NFM Rises Q/Q
by Zacks Equity Research
EQIX tops Q2 AFFO and revenue estimates as recurring revenues grow and cabinet equivalent capacity expands despite non-recurring revenues weakness.
Welltower's Q2 FFO & Revenues Beat Estimates, Same Store NOI Rises
by Zacks Equity Research
WELL's Q2 FFO outshines estimates, driven by a rise in revenues. Same Store NOI improves year over year.
Healthpeak Q2 FFO Meets Estimates, Same-Store NOI Rises Y/Y
by Zacks Equity Research
DOC's second-quarter results reflect the continued strong performance of its high-quality lab, outpatient medical and CCRC portfolios.
Healthpeak (DOC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Healthpeak (DOC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Healthpeak (DOC) Q2 FFO Meet Estimates
by Zacks Equity Research
Healthpeak (DOC) delivered FFO and revenue surprises of 0.00% and -0.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Healthpeak Properties This Earnings Season?
by Zacks Equity Research
DOC's Q2 earnings are likely to benefit from rising healthcare spending and the aging population. However, higher interest expenses may have hurt it.
Healthpeak (DOC) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Get a deeper insight into the potential performance of Healthpeak (DOC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Why Healthpeak (DOC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is it Wise to Retain Healthpeak Properties Stock in Your Portfolio?
by Zacks Equity Research
DOC is likely to gain from solid demand for lab assets and rising senior citizens' healthcare spending despite high competition and debt burden.
Here's Why Healthpeak (DOC) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Rayonier's Q1 Earnings Miss Estimates, Revenues Decline Y/Y
by Zacks Equity Research
RYN's Q1 earnings reflect a decline in pro-forma operating income from its Southern Timber and Real Estate segments.
Ventas Q1 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises
by Zacks Equity Research
VTR's Q1 results reflect higher same-store cash NOI due to SHOP same-store average occupancy growth.
American Tower Stock Gains on Q1 AFFO Beat, Revenues Rise Y/Y
by Zacks Equity Research
AMT's Q1 results reflect a year-over-year rise in revenues, led by property and service operations segment revenues. Strong organic tenant billing growth aids results.
Welltower's Q1 FFO & Revenues Beat Estimates, Same Store NOI Rises
by Zacks Equity Research
WELL's Q1 FFO outshines estimates, driven by a rise in revenues. Same Store NOI improves year over year.
Healthpeak's Q1 FFO Meets Estimates, Same-Store NOI Rises
by Zacks Equity Research
DOC's Q1 results reflect the continued strong performance of its high-quality lab, outpatient medical and CCRC portfolios.
Here's What Key Metrics Tell Us About Healthpeak (DOC) Q1 Earnings
by Zacks Equity Research
The headline numbers for Healthpeak (DOC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Healthpeak (DOC) Q1 FFO Meet Estimates
by Zacks Equity Research
Healthpeak (DOC) delivered FFO and revenue surprises of 0% and 0.98%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
How to Find Strong Finance Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What's in the Cards for Healthpeak Properties This Earnings Season?
by Zacks Equity Research
DOC's Q1 earnings are likely to have benefited from rising healthcare spending and the aging population. However, higher interest expenses may have hurt it.
Countdown to Healthpeak (DOC) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Healthpeak (DOC) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Vornado (VNO) Surges 10.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Vornado (VNO) was a big mover last session on higher-than-average trading volume. The latest trend in FFO per share estimate revisions might help the stock continue moving higher in the near term.
Want Better Returns? Don?t Ignore These 2 Finance Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.